NYSE:NVS - Novartis Stock Price, Forecast & News

Novartis trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVS."

Novartis announced an annual dividend on Monday, February 3rd. Stockholders of record on Wednesday, March 4th will be paid a dividend of $3.0425 per share on Thursday, March 12th. This represents a dividend yield of 2%. The ex-dividend date of this dividend is Tuesday, March 3rd. This is an increase from Novartis's previous annual dividend of $2.86. View Novartis' Dividend History.

Novartis AG (NYSE:NVS) issued its earnings results on Tuesday, October, 22nd. The company reported $1.41 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.31 by $0.10. The company had revenue of $12.17 billion for the quarter, compared to the consensus estimate of $11.67 billion. Novartis had a return on equity of 23.39% and a net margin of 24.73%. The firm's quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year, the business posted $1.32 EPS. View Novartis' Earnings History.

Novartis is scheduled to release their next quarterly earnings announcement on Wednesday, April 22nd 2020. View Earnings Estimates for Novartis.

9 brokerages have issued 12 month target prices for Novartis' shares. Their forecasts range from $79.16 to $105.00. On average, they anticipate Novartis' stock price to reach $91.67 in the next year. This suggests a possible upside of 6.6% from the stock's current price. View Analyst Price Targets for Novartis.

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Novartis in the last year. There are currently 2 sell ratings, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Novartis.

Headlines about NVS stock have trended extremely negative recently, InfoTrie Sentiment reports. The research group identifies positive and negative press coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Novartis earned a coverage optimism score of -4.2 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Novartis.

Novartis saw a increase in short interest in the month of February. As of February 14th, there was short interest totalling 4,030,000 shares, an increase of 10.4% from the January 30th total of 3,650,000 shares. Based on an average trading volume of 1,620,000 shares, the short-interest ratio is presently 2.5 days. Currently, 0.2% of the company's shares are sold short. View Novartis' Current Options Chain.

Some companies that are related to Novartis include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Pfizer (PFE), Novo Nordisk A/S (NVO), Abbott Laboratories (ABT), AbbVie (ABBV), Eli Lilly And Co (LLY), Sanofi (SNY), AstraZeneca (AZN), GlaxoSmithKline (GSK), Bristol-Myers Squibb (BMY), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Bayer (BAYRY).

Based on aggregate information from My MarketBeat watchlists, some companies that other Novartis investors own include Johnson & Johnson (JNJ), AbbVie (ABBV), Walt Disney (DIS), Pfizer (PFE), Intel (INTC), AT&T (T), Cisco Systems (CSCO), NVIDIA (NVDA), Merck & Co., Inc. (MRK) and Verizon Communications (VZ).

Novartis' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Franklin Resources Inc. (0.51%), Loomis Sayles & Co. L P (0.45%), Bank of America Corp DE (0.41%), Renaissance Technologies LLC (0.29%), Mawer Investment Management Ltd. (0.26%) and FMR LLC (0.26%).

NVS stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Franklin Resources Inc., State Street Corp, Fort Washington Investment Advisors Inc. OH, Manning & Napier Group LLC, Partner Fund Management L.P., Boston Partners and Schafer Cullen Capital Management Inc.

NVS stock was acquired by a variety of institutional investors in the last quarter, including Loomis Sayles & Co. L P, Jennison Associates LLC, Renaissance Technologies LLC, Westfield Capital Management Co. LP, Bank of America Corp DE, Madison Asset Management LLC, Bain Capital Public Equity Management II LLC and Magnetar Financial LLC.

Shares of NVS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of NVS stock can currently be purchased for approximately $86.02.

Novartis has a market capitalization of $197.14 billion and generates $47.50 billion in revenue each year. The company earns $11.73 billion in net income (profit) each year or $5.24 on an earnings per share basis. Novartis employs 103,914 workers across the globe.View Additional Information About Novartis.

The official website for Novartis is http://www.novartis.com/.

Novartis' mailing address is LICHTSTRASSE 35, BASEL V8, CH 4056. The company can be reached via phone at 41-61-324-1111 or via email at [email protected]